Evidence map›Paper›PMID 35320392›Full record

ArticleHeart and vessels2022

Native T1 heterogeneity for predicting reverse remodeling in patients with non-ischemic dilated cardiomyopathy.

Minori Kinoshita, Shingo Kato, Sho Kodama, Mai Azuma, Naoki Nakayama, Kazuki Fukui, Naka Saito, Tae Iwasawa, Kazuo Kimura, Kouichi Tamura and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Minori Kinoshita *Department of Diagnostic Radiology, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Shingo Kato *Department of Diagnostic Radiology, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan. sk513@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-7545-0669
Sho KodamaDepartment of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Mai AzumaDepartment of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Naoki NakayamaDepartment of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Kazuki FukuiDepartment of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Naka SaitoDepartment of Diagnostic Radiology, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Tae IwasawaDepartment of Radiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Kazuo KimuraDepartment of Cardiology, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Daisuke UtsunomiyaDepartment of Diagnostic Radiology, Graduate School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan.
Kanagawa Cardiovascular and Respiratory Center · JPYokohama City University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A recent study has shown that the heterogeneity of native T1 mapping may be a new prognostic factor for patients with non-ischemic dilated cardiomyopathy (NIDCM). This study aimed to investigate the predictive value of native T1 heterogeneity of the left ventricular (LV) myocardium, as assessed by pixel-wise histogram analysis, for predicting left ventricular reverse remodeling (LVRR) by medical therapy in patients with NIDCM. A total of one hundred and thirteen NIDCM patients (mean age: 63 ± 12 years; 91 males and 22 females; mean LV ejection fraction (EF): 37 ± 10%) were retrospectively analyzed. T1 mapping images were acquired using a modified look-locker inversion recovery (MOLLI) sequence. We performed histogram analysis of native T1 mapping of LV myocardium, mean (T1-mean) and standard deviation (T1-STD) of native T1 time from each pixel were calculated. Extracellular volume fraction (ECV) was also evaluated. LVRR was defined as LVEF increased ≥ 10% points and decrease in LV end-diastolic volume ≥ 10% at 12 months from initiation of medical therapy. Cutoff value of T1-mean and T1-STD was set as median value of each parameter. Sixty (53%) NIDCM patients reached LVRR. Area under the receiver-operating characteristics curve for predicting LVRR was 0.763 (95% confidence interval (CI) 0.679-0.847) for %LGE, 0.757 (95% CI 0.663-0.850) for T1-mean, 0.724 (95% CI 0.625-0.823) for T1-STD, 0.800 (95% CI 0.717-0.882) for ECV, respectively. Proportion of LVRR was significantly lower in NIDCM patients with high T1-mean and high T1-STD (12%) compared to NIDCM with high T1-mean and low T1-STD (65%) (p < 0.001). Adding T1-STD to T1-mean improved AUC from 0.757 to 0.806, comparable to AUC of ECV. Combination of T1-mean and T1-STD, a parameter of heterogeneity of native T1 of the LV myocardium, may be a useful for prediction of LVRR by medical therapy without use of gadolinium contrast for patients with NIDCM.

Indexed as

Cardiomyopathy, DilatedVentricular RemodelingAgedContrast MediaFemaleHeart VentriclesHumansMagnetic Resonance Imaging, CineMaleMiddle AgedMyocardiumPredictive Value of TestsRetrospective StudiesVentricular Function, LeftContrast MediaExtracellular volume fractionHeterogeneityHistogram analysisMagnetic resonanceNon-ischemic dilated cardiomyopathyT1 mapping

Identifiers

PMID35320392
OpenAlexW4220779109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.